WCN26-3782 CYTOMEGALOVIRUS REACTIVATION IN PATIENTS WITH MICROSCOPIC POLYANGIITIS TREATED WITH RITUXIMAB: A RETROSPECTIVE COMPARATIVE STUDY

Read full text Summarise with VIRAT
Authors: Yosuke Imamura, Mariko Kawamura, Daisuke Katagiri, Naoto Eriguchi, Harui Bamba, Mimiko Matsumura, Minami Suzuki, Hideki Takano
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Rituximab (RTX) is an effective agent for both remission induction and maintenance therapy in microscopic polyangiitis (MPA). However, cytomegalovirus (CMV) reactivation due to RTX-induced immunosuppression remains a serious adverse event. Data regarding the high-risk period for CMV reactivation and optimal surveillance strategies are limited.

Fields of Study & Subjects

Cytomegalovirus and herpesvirus research Vasculitis and related conditions Viral-associated cancers and disorders

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106207–106207
Publication date
25 March 2026
Language
EN